Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study
Authors
Keywords
-
Journal
Multiple Sclerosis Journal
Volume -, Issue -, Pages 135245852210839
Publisher
SAGE Publications
Online
2022-04-01
DOI
10.1177/13524585221083982
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Use of disease-modifying drugs during pregnancy and breastfeeding
- (2021) Ruth Dobson et al. CURRENT OPINION IN NEUROLOGY
- The Gut‒Breast Axis: Programming Health for Life
- (2021) Juan M. Rodríguez et al. Nutrients
- Treatment of Women with Multiple Sclerosis Planning Pregnancy
- (2021) Kristen M. Krysko et al. Current Treatment Options in Neurology
- Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience
- (2020) Aurora Zanghì et al. Frontiers in Neurology
- Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort
- (2020) Annette Langer-Gould et al. NEUROLOGY
- Safety of potential breast milk exposure to IFN-β or glatiramer acetate
- (2020) Andrea Ines Ciplea et al. Neurology-Neuroimmunology & Neuroinflammation
- Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
- (2020) Madeline Bross et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pregnancy with multiple sclerosis
- (2020) S. Vukusic et al. REVUE NEUROLOGIQUE
- Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis
- (2019) Sarah C. MacDonald et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Breastfeeding and post-partum relapses in multiple sclerosis patients
- (2019) Emilio Portaccio et al. Multiple Sclerosis Journal
- Breastfeeding and neurodevelopmental outcomes
- (2018) Bernardo L. Horta et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Treatment of multiple sclerosis during pregnancy – safety considerations
- (2017) Jan Thöne et al. Expert Opinion On Drug Safety
- Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding
- (2017) Rhonda Voskuhl et al. Neurotherapeutics
- Glatiramer acetate during early pregnancy: A prospective cohort study
- (2016) Sandra Herbstritt et al. Multiple Sclerosis Journal
- Glatiramer acetate during early pregnancy: A prospective cohort study
- (2016) Sandra Herbstritt et al. Multiple Sclerosis Journal
- Breastfeeding and maternal health outcomes: a systematic review and meta-analysis
- (2015) Ranadip Chowdhury et al. ACTA PAEDIATRICA
- Drugs in Breast Milk
- (2015) EDWARD R. NEWTON et al. CLINICAL OBSTETRICS AND GYNECOLOGY
- Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses
- (2015) Kerstin Hellwig et al. JAMA Neurology
- Pregnancy in Multiple Sclerosis
- (2014) Kerstin Hellwig EUROPEAN NEUROLOGY
- Management of Multiple Sclerosis During Pregnancy and the Reproductive Years
- (2014) Riley Bove et al. OBSTETRICS AND GYNECOLOGY
- Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
- (2012) Marta Giannini et al. BMC Neurology
- Sex-related factors in multiple sclerosis susceptibility and progression
- (2012) Rhonda R. Voskuhl et al. Nature Reviews Neurology
- Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis
- (2010) Kerstin Hellwig et al. JOURNAL OF NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More